Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

Number of Participants Discontinuing the Trial by Visit (Week)

The number of participants who discontinued by visit (non-cumulative).

Time frame: Visit 2 (Baseline) to Visit 7 (Week 16)

Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale

Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in Blood Pressure

Sitting blood pressure, taken from the same arm.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)

Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose

Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin

Patients should be fasting a minimum of eight hours prior to serum insulin measurement.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)

HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Number of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint

Patient meets definition of metabolic syndrome if they have \>=3 risk factors: Waist circumference (men\>102cm, women\>88cm); triglycerides \>=1.7mmol/L; HDL cholesterol (men\<1.04mmol/L, women\<1.30mmol/L); blood pressure \>135/\>=85 mmHg; Fasting glucose \>=6.1mmol/L

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale

Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale

Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale

Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning).

Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)